GENEVA, July 18 -- CEREVANCE GAMMA, INC filed a patent application (GB2026/050033) for “COMBINATION OF CVN-766 AND A GLP-1 RECEPTOR AGONIST FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT”. With publication no. WO/2026/150221, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 31/497
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....